Journal of Medicinal Chemistry · 2017 · 134 citations · 31 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyMtor Inhibitor TherapyTargeted Cancer TherapyTargeted TherapyMtor InhibitionMtor SignalingPharmacokinetic ParametersPi3k InhibitorsPi3k SignalingPi3k-akt Signaling PathwayProtein Kinase B SignalingProtein Kinase Inhibitors
Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays. Moreover, 1 did not bind tubulin, which was observed for the structurally related 4 (BKM120, buparlisib). Compound 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound's safety profile, identifies 1 as a clinical candidate with a broad application range in oncology, including treatment of brain tumors or CNS metastasis. Compound 1 is currently in phase II clinical trials for advanced solid tumors and refractory lymphoma.
31
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +16